Abstract
Purpose
To evaluate differences in the viscosity of a platinum iodized-oil suspension on the kind of platinum agent and temperature.
Materials and methods
Viscosities of a 70 mg miriplatin and 3.5 ml iodized-oil suspension (MO suspension) and that of 100 mg cisplatin and 10 ml iodized-oil suspension (CO suspension) were evaluated at three temperatures: 25, 37, and 50 °C. Iodized-oil was used as the control. Each liquid was injected into a capillary tube and allowed to drip separately. The liquid transit time was measured, and the viscosity of each liquid was calculated at each temperature.
Results
The viscosity of each liquid decreased as the temperature increased: 43.3 ± 0.5, 39.2 ± 0.7, and 34.7 ± 0.6 mPa s for MO suspension, 41.3 ± 0.2, 36.9 ± 0.3, and 32.7 ± 0.9 mPa s for CO suspension, and 40.5 ± 0.2, 36.8 ± 0.2, and 33.8 ± 0.7 mPa s for iodized-oil at 25, 37, and 50 °C, respectively. The MO suspension group viscosity was significantly higher than that of the CO suspension group (p < 0.05) and the control (p < 0.05). Significant differences were found in viscosities among groups divided by temperature (25 °C-group vs. 37 °C-group, p < 0.05; 37 °C-group vs. 50 °C-group, p < 0.05).
Conclusion
The viscosity of the platinum iodized-oil suspension can be adjusted by changing temperature.
This is a preview of subscription content, log in via an institution to check access.
References
Nakamura H, Hashimoto T, Oi H, et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989;170(3 Pt 1):783–6.
Nakao N, Uchida H, Kamino K, et al. Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis. Cardiovasc Intervent Radiol. 1994;17(2):76–80.
Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47–54.
Ikeda M, Maeda S, Ashihara H, et al. Transcatheter arterial infusion chemotherapy with cisplatin–lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol. 2010;45(1):60–7.
Takaki Y, Kaminou T, Shabana M, et al. Suitable blending method of lipiodol–cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature. Hepatogastroenterology. 2008;55(81):202–6.
Beppu T, Sugimoto K, Shiraki K, et al. Clinical utility of transarterial infusion chemotherapy using cisplatin–lipiodol emulsion for unresectable hepatocellular carcinoma. Anticancer Res. 2012;32(11):4923–30.
Okusaka T, Kasugai H, Ishii H, et al. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (miriplatin) for hepatocellular carcinoma. Invest New Drugs. 2012;30(5):2015–25.
Watanabe S, Nitta N, Ohta S, et al. Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin). Cardiovasc Intervent Radiol. 2012;35(2):399–405.
Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of L-TAE with farmorubicin and L-TAE with adriamycin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992;31:97–102.
Yamashita Y, Takahashi M, Fujimura N, et al. Clinical evaluation of hepatic artery embolization: comparison between gelfoam and lipiodol with anticancer agent. Radiat Med. 1987;5(3):61–7.
Hamuro M, Nakamura K, Sakai Y, et al. New oily agents for targeting chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 1999;22(2):130–4.
Miyayama S, Yamashiro M, Shibata Y, et al. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol. 2012;30(3):263–70.
Kora S, Higashihara H, Urakawa H, et al. Heating effect of miliplatin lipiodol suspension. J N Remedies Clin. 2011;60(5):994–8.
Package insert of MIRIPLA suspension vehicle. Dainippon Sumitomo Pharma. http://database.japic.or.jp/pdf/newPINS/00058257.pdf (Accessed September 16, 2012).
Package insert of MIRIPLA. Dainippon Sumitomo Pharma. http://database.japic.or.jp/pdf/newPINS/00058256.pdf (Accessed September 16, 2012).
Package insert of IA-call Nippon Kayaku. http://database.japic.or.jp/pdf/newPINS/00050614.pdf (Accessed September 16, 2012).
White FM. Viscous fluid flow. 2nd ed. New York: McGraw Hill Inc; 1991. p. 26–31.
Student resources for general chemistry; viscosity http://chemed.chem.wisc.edu/chempaths/GenChem-Textbook/Viscosity-840.html (Accessed October 28, 2012).
Paul Hiemenz C, Lodge P Timothy. Polymer chemistry. 2nd ed. Boca Raton: CRC Press; 2007. p. 336–9.
Kishimoto S, Noguchi T, Yamaoka T, et al. In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N′)bis(myristato)] platinum(II) suspended in lipiodol. Biol Pharm Bull. 2000;23(5):637–40.
Hughes AJ. The Einstein relation between relative viscosity and volume concentration of suspensions of spheres. Nature. 1954;173:1089–90.
Yamanaka T, Yamakado K, Takaki H, et al. Ablative zone size created by radiofrequency ablation with and without chemoembolization in small hepatocellular carcinomas. Jpn J Radiol. 2012;30(7):553–9.
Yamakado K, Nakatsuka A, Takaki H, et al. Early stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology. 2008;247(1):260–6.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hasegawa, T., Takaki, H., Yamanaka, T. et al. Experimental assessment of temperature influence on miriplatin and cisplatin iodized-oil suspension viscosity. Jpn J Radiol 31, 424–427 (2013). https://doi.org/10.1007/s11604-013-0201-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-013-0201-0